Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Mar 10;100(7):1154–1164. doi: 10.1038/sj.bjc.6604969

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2009 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

In vivo anti-tumour activity of CRAd-S-pk7 in combination with TMZ. (A) Five consecutive injections of TMZ at 70 mg kg⁻¹ per day (▾) achieve 100% survival for 80 days after U87MG implantation, whereas five TMZ injections at 10 mg kg⁻¹ per day (○) had significant increase in survival compared with mock treatment (•) (P<0.05). (B) Single intracranial (i.c.) injection of CRAd-S-pk7 at 5 × 10⁹ vp per mouse (▵) achieves significant increase in survival compared with mice that received two (○) or one (▾) injection of CRAd-S-pk7 at a dose of 3 × 10⁹ vp per mouse or mock control (•) (P<0.05) (C) Five consecutive injections of TMZ at 10 mg kg⁻¹ per day followed by two CRAd-S-pk7 treatments each at 3 × 10⁹ vp per mouse (Δ) showed significant additive effect on mice survival compared with mock (▪) (P<0.02), double injections of CRAd-S-pk7 each at 3 × 10⁹ vp per mouse (▵) (P<0.02) or five consecutive injections of TMZ at 10 mg kg⁻¹ per day (▾) (P<0.02).